Equillium announces results of the phase 3 equator study of itolizumab in first-line treatment of patients with acute graft-versus-host disease

La jolla, calif.--(business wire)---- $eq #gvhd--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced topline data from the phase 3 equator study evaluating itolizumab in first-line treatment of patients with acute graft-versus-host disease (agvhd). the study results did not demonstrate a meaningful difference in complete response (cr) or overal.
EQ Ratings Summary
EQ Quant Ranking